Aspira Women's Health Files Q3 2024 10-Q

TL;DR

Aspira Women's Health filed its Q3 2024 10-Q. Check financials.

AI Summary

Aspira Women's Health Inc. filed a 10-Q for the period ending September 30, 2024. The filing covers the third quarter and the first nine months of the fiscal year. Key financial data and business operations for this period are detailed within the report.

Why It Matters

This filing provides investors with the latest financial performance and operational updates for Aspira Women's Health, crucial for understanding the company's current standing and future prospects.

Risk Assessment

Risk Level: medium — 10-Q filings are standard for public companies, but the specific financial health and operational details within this report will determine the actual risk.

Key Numbers

• 2024-09-30 — Reporting Period End Date (Indicates the end of the fiscal quarter and year-to-date period covered by the report.)
• 2024-11-19 — Filing Date (The date the 10-Q was officially submitted to the SEC.)

Key Players & Entities

• Aspira Women's Health Inc. (company) — Filer of the 10-Q
• 2024-09-30 (date) — End of the reporting period
• 2024-11-19 (date) — Filing date
• VERMILLION, INC. (company) — Former company name
• CIPHERGEN BIOSYSTEMS INC (company) — Former company name
• ABIOTIC SYSTEMS (company) — Former company name

FAQ

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share AWH The Nasdaq Capital Ma

Filing Documents

• form10-q.htm (10-Q) — 1154KB
• ex31-1.htm (EX-31.1) — 17KB
• ex31-2.htm (EX-31.2) — 17KB
• ex32-1.htm (EX-32.1) — 13KB
• 0001493152-24-046836.txt ( ) — 6079KB
• awh-20240930.xsd (EX-101.SCH) — 46KB
• awh-20240930_cal.xml (EX-101.CAL) — 49KB
• awh-20240930_def.xml (EX-101.DEF) — 220KB
• awh-20240930_lab.xml (EX-101.LAB) — 408KB
• awh-20240930_pre.xml (EX-101.PRE) — 312KB
• form10-q_htm.xml (XML) — 872KB

Financial Statements (unaudited)

Financial Statements (unaudited) 1 Condensed Consolidated Balance Sheets as of September 30, 2024 and December 31, 2023 1 Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2024 and 2023 2 Condensed Consolidated Statements of Changes in Stockholders' (Deficit) Equity for the three and nine months ended September 30, 2024 and 2023 3 Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2024 and 2023 5 Notes to Condensed Consolidated Financial Statements 6 Item 2

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 20 Item 3

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 34 Item 4

Controls and Procedures

Controls and Procedures 34 PART II Other Information 35 Item 1

Legal Proceedings

Legal Proceedings 35 Item 1A

Risk Factors

Risk Factors 35 Item 2 Unregistered Sales of Equity Securities and Use of Proceeds 35 Item 3 Defaults Upon Senior Securities 35 Item 4 Mine Safety Disclosures 35 Item 5 Other Information 35 Item 6 Exhibits 36

SIGNATURES

SIGNATURES 37 The following are registered and unregistered trademarks and service marks of Aspira Women's Health Inc.: VERMILLION SM , Aspira Women's Health , OVA1 , OVERA , ASPiRA LABS , OvaCalc , OVASUITE SM , ASPiRA GenetiX SM , OVA1PLUS , OVAWATCH , EndoCheck SM , ENDOINFORM TM , OVAINFORM TM , OVAInherit SM , Aspira Synergy , OVA360 SM , ASPIRA IVD SM , and YOUR HEALTH, OUR PASSION . i PART I - FINANCIAL INFORMATION ITEM 1. FINANCIAL STATEMENTS Aspira Women's Health Inc. Condensed Consolidated Balance Sheets (unaudited) (Amounts in Thousands, Except Share and Par Value Amounts) September 30, December 31, 2024 2023 Assets Current assets: Cash and cash equivalents $ 2,133 $ 2,597 Accounts receivable, net of reserves of $ 0 and $ 15 , as of September 30, 2024 and December 31, 2023, respectively 1,254 1,459 Prepaid expenses and other current assets 436 997 Inventories 290 227 Total current assets 4,113 5,280 Property and equipment, net 99 165 Right-of-use assets 515 528 Restricted cash - 258 Other assets 32 31 Total assets $ 4,759 $ 6,262 Liabilities and Stockholders' Deficit Current liabilities: Accounts payable $ 2,551 $ 1,261 Accrued liabilities 2,494 2,863 Current portion of long-term debt 229 166 Short-term debt - 670 Current maturities of lease liabilities 192 159 Total current liabilities 5,466 5,119 Non-current liabilities: Long-term debt 1,334 1,430 Non-current maturities of lease liabilities 387 427 Warrant liabilities 92 1,651 Total liabilities 7,279 8,627 Commitments and contingencies (Note 4) - Stockholders' deficit: Common stock, par value $ 0.001 per share, 200,000,000 and 200,000,000 shares authorized at September 30, 2024 and December 31, 2023, respectively; 16,284,381 and 10,645,049 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively 16 11 Additional paid-in capital 527,473 515,927 Accum

View Full Filing

View this 10-Q filing on SEC EDGAR